OBJECTIVES: We investigated whether serum levels of an alternatively spliced soluble (s)TNF receptor-2 (DS-TNFR2) affected the clinical response to anti-TNF-α therapy, classical DMARDs or radiological evidence of disease progression in patients with RA. METHODS: We included 116 patients with RA. Cohort 1: 52 DMARD-naïve early RA patients [mean (s.d.) disease duration 8.5 (6.2) months] who started gold salts and MTX therapies. Cohort 2: 64 MTX-resistant established RA patients [144 (107) months] who started infliximab therapy. We evaluated the European League Against Rheumatism (EULAR) response to therapy and the serum levels of DS-TNFR2, sTNFR2 and ACPAs at baseline and at 12 months. In Cohort 1, radiological progression and levels of MMP-1 were also determined. RESULTS: In Cohort 1, 40% of patients had high baseline levels (HL > 50 ng/ml) of DS-TNFR2 with significantly higher RF and ACPA levels than patients with normal levels (NL ≤ 50 ng/ml) of DS-TNFR2. The EULAR response to DMARDs was similar in HL and NL patients. Radiographic progression was observed in 23.5% of all patients after 12 months. In Cohort 2, 26.6% of patients had HL of DS-TNFR2 with significantly higher RF and ACPA levels than patients with NLs. The EULAR response from 6 to 30 weeks was prolonged in the HL group compared with the NL group. CONCLUSIONS: Patients with HL of DS-TNFR2 maintained a prolonged therapeutic response to anti-TNF-α therapy and had proportionally less radiographic progression compared with patients with NLs.
OBJECTIVES: We investigated whether serum levels of an alternatively spliced soluble (s)TNF receptor-2 (DS-TNFR2) affected the clinical response to anti-TNF-α therapy, classical DMARDs or radiological evidence of disease progression in patients with RA. METHODS: We included 116 patients with RA. Cohort 1: 52 DMARD-naïve early RApatients [mean (s.d.) disease duration 8.5 (6.2) months] who started gold salts and MTX therapies. Cohort 2: 64 MTX-resistant established RApatients [144 (107) months] who started infliximab therapy. We evaluated the European League Against Rheumatism (EULAR) response to therapy and the serum levels of DS-TNFR2, sTNFR2 and ACPAs at baseline and at 12 months. In Cohort 1, radiological progression and levels of MMP-1 were also determined. RESULTS: In Cohort 1, 40% of patients had high baseline levels (HL > 50 ng/ml) of DS-TNFR2 with significantly higher RF and ACPA levels than patients with normal levels (NL ≤ 50 ng/ml) of DS-TNFR2. The EULAR response to DMARDs was similar in HL and NL patients. Radiographic progression was observed in 23.5% of all patients after 12 months. In Cohort 2, 26.6% of patients had HL of DS-TNFR2 with significantly higher RF and ACPA levels than patients with NLs. The EULAR response from 6 to 30 weeks was prolonged in the HL group compared with the NL group. CONCLUSIONS:Patients with HL of DS-TNFR2 maintained a prolonged therapeutic response to anti-TNF-α therapy and had proportionally less radiographic progression compared with patients with NLs.
Authors: Dalin Li; Mark S Silverberg; Talin Haritunians; Marla C Dubinsky; Carol Landers; Joanne M Stempak; Raquel Milgrom; Xiuqing Guo; Yii-Der Ida Chen; Jerome I Rotter; Kent D Taylor; Dermot P B McGovern; Stephan R Targan Journal: Inflamm Bowel Dis Date: 2016-06 Impact factor: 5.325
Authors: A Verwoerd; D Hijdra; A D M Vorselaars; H A Crommelin; C H M van Moorsel; J C Grutters; A M E Claessen Journal: Clin Exp Immunol Date: 2016-07-12 Impact factor: 4.330
Authors: Alejandro Ibáñez-Costa; Carlos Perez-Sanchez; Alejandra María Patiño-Trives; Maria Luque-Tevar; Pilar Font; Ivan Arias de la Rosa; Cristobal Roman-Rodriguez; Mª Carmen Abalos-Aguilera; Carmen Conde; Antonio Gonzalez; Sergio Pedraza-Arevalo; Mercedes Del Rio-Moreno; Ricardo Blazquez-Encinas; Pedro Segui; Jerusalem Calvo; Rafaela Ortega Castro; Alejandro Escudero-Contreras; Nuria Barbarroja; Mª Angeles Aguirre; Justo P Castaño; Raul M Luque; Eduardo Collantes-Estevez; Chary Lopez-Pedrera Journal: Ann Rheum Dis Date: 2021-10-08 Impact factor: 19.103
Authors: Eduardo López-Urrutia; Alma Campos-Parra; Luis Alonso Herrera; Carlos Pérez-Plasencia Journal: Oncol Lett Date: 2017-09-06 Impact factor: 2.967